UNSPSC 51262903: Levomoprolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4NON6FSON, chemically known as 2-propanol, 1-(2-methoxyphenoxy)-3-((1-methylethyl)amino)-, (s)- but generally known as levomoprolol, which bears US NIH Compound Identifier 3034006. European Medicines Agency schedules Levomoprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08480MIG.

UNSPSC 51262903 Levomoprolol is a Commodity code that in recent state and local practice encompasses procurement of pharmaceutical products and drug-management systems for public health initiatives, rather than levomoprolol specifically. State and local health agencies and county governments use this code to solicit naloxone, drug deactivation systems, and related pharmacy benefit management services. The issuing bodies include county health departments and state health and human services commissions pursuing competitive bidding and request-for-information processes to source these products and to explore direct-to-manufacturer pharmacy contracting models. Work under the code ranges from routine procurement of overdose-reversal medications and controlled-substance management systems to strategic market research on pharmacy benefit program restructuring and direct contracting capabilities.

Recent activity appears concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor intelligence on implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, requesting information from vendors on direct contracting capacity, negotiated net pricing models, and value-based agreement capabilities. The RFI functioned as a preliminary market research mechanism to inform future formal solicitations rather than as a binding competitive bid.